Tag: dmt

The Rise of legal DMT in the Psychedelic Conversation: As discussions around psychedelic legalization continue to evolve, one substance has gained notable traction: DMT (N,N-Dimethyltryptamine). Known for its intense, short-acting hallucinogenic experience, DMT has historically remained in the shadows compared to psilocybin or LSD. But now, thanks to changing perceptions and renewed research, the movement toward legalizing DMT is growing louder.

Legal DMT? A Patchwork of Global Policies

While DMT remains a Schedule I substance in the U.S. under the Controlled Substances Act, exceptions exist. Religious groups, such as the União do Vegetal (UDV), have received legal protection for ceremonial use of ayahuasca, a DMT-containing brew. Meanwhile, countries like Brazil and Peru tolerate traditional and spiritual use. In Canada, Section 56 exemptions are being considered for DMT therapy, and several psychedelic startups are lobbying for rescheduling.

Why DMT Is Different

Unlike other psychedelics, DMT offers a rapid and immersive experience — often lasting just 10–20 minutes when inhaled or vaped. This brevity makes it attractive for potential clinical applications, such as fast-acting trauma interventions or consciousness research. Companies like Small Pharma in the UK are developing DMT-based treatments for depression, and early-stage results are promising.

The Ethical and Medical Questions

However, the intensity and unpredictability of the DMT experience raises ethical concerns. Critics argue that even in supervised settings, the sheer strangeness of the DMT “breakthrough” could be destabilizing for vulnerable patients. Others emphasize that more controlled studies are needed to determine optimal dosing and preparation methods.

Cultural Roots vs. Commercial Interests

There’s also a growing dialogue about cultural appropriation, particularly regarding 5-MeO-DMT from toads and DMT-containing plants used in Amazonian traditions. Legalization efforts must balance respect for indigenous knowledge with the interests of Western medical and commercial frameworks.

Market Implications and Public Reception

If legalized, DMT could create a new niche within the psychedelic therapeutics market, projected to reach $10 billion by 2027. Yet public perception still lags behind psilocybin. Many associate DMT with “trip reports” and underground chemists rather than structured medical environments — a barrier advocates must overcome.

Keep reading

The psychedelic substances 5-MeO-DMT causes a long-lasting increase in the number of tiny protrusions called dendritic spines in the brain, according to new research published in Neuropsychopharmacology. The study, which was conducted on mice, sheds light on the behavioral and neural mechanisms of 5-MeO-DMT.

Serotonergic psychedelics (such as psilocybin and LSD) have shown promise as potential therapeutics for mental illnesses like depression and anxiety. Short-acting compounds are particularly interesting because they require less dosing time, which could improve patient access to treatment. In humans, 5-MeO-DMT produces a short-lasting experience due to its rapid breakdown in the body.

“My lab started research on psychiatric drugs like ketamine and psychedelics about 10 years ago. We were motivated by how basic science and clinical research can together powerfully move a drug forward to become medicine. Specifically I believe there is a lot of potential for psychedelics as therapeutics, and that drives our interest in this topic,” said study author Alex Kwan (@kwanalexc), an associate professor in the Meinig School of Biomedical Engineering at Cornell University.

5-MeO-DMT, found in the Sonoran Desert toad, has some unique pharmacological properties. It targets serotonin receptors, specifically the 5-HT1A and 5-HT2A subtypes, similar to psilocybin but with a higher affinity for 5-HT1A receptors. However, little is known about the long-term effects of 5-MeO-DMT. To address this, the researchers conducted a study using mice.

Keep reading